Printer Friendly

India : BHARAT Biotech launches 4G Typhoid vaccine.

A new typhoid vaccine claimed to be the world s first clinically proven typhoid conjugate vaccine is introduced by the Bharat Biotech International Ltd.

Rs 65 crore were spend by the privately-held company to develop the vaccine in a period of 8 years of internal R&D, is at present aiming a business of Rs 100 crore from this segment.

At present, Bharat Biotech creates and markets a third-generation typhoid vaccine, which adds about Rs 50 crore in income.

Krishna Ella, CMD, Bharat Biotech said, This is the first typhoid conjugate vaccine to get a licence after going through the full scale clinical trial process .

Presently available Typhoid vaccines fall short of two major aspects long-term protection and protection for children below 2 years, an age group that s mostly affected.

Ella added, We hope this vaccine will reach millions of people and help reduce the burden of this devastating disease in infants and children .

A dual pricing model for public and the private market will be followed by Bharat Biotech, which exports a large volume of typhoid vaccines to Pakistan and Bangladesh for both civilian and army requirements.

2013 Al Bawaba (

Provided by an company
COPYRIGHT 2013 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Aug 28, 2013
Previous Article:India : NIT and HP signs MoU.
Next Article:India : Sports Minister Shri Jitendra Singh hands over A Cheque of Rs. 2 Lakh to Smt. Sulinder Kaur, Widow of Late Shri Makhan Singh.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters